Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ICN
|
|||
| Former ID |
DIB010768
|
|||
| Drug Name |
DuP-630
|
|||
| Indication | Dermatitis [ICD-11: EA80-EA89; ICD-9: 692.9] | Terminated | [1] | |
| Company |
Bristol-Myers Squibb Pharma Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytochrome P450 reductase (P450) | Target Info | Modulator | [2] |
| BioCyc | Superpathway of tryptophan utilization | |||
| Superpathway of melatonin degradation | ||||
| Melatonin degradation I | ||||
| Vitamin D<sub>3</sub> biosynthesis | ||||
| Bile acid biosynthesis, neutral pathway | ||||
| WikiPathways | Oxidation by Cytochrome P450 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003777) | |||
| REF 2 | CN patent application no. 1096855, Composition produced by treatment and induction of nitrogen mono oxide synthase expressed matter, and use thereof. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.